CRA consultants assessed whether disputed representations of bioequivalence significantly affected sales of the branded product. The evaluation included consideration of distribution channels, purchase timing, and the effect of payor control mechanisms on product uptake and sales. The case ultimately resulted in a settlement.
IP Literature Watch: May 2023
In this month’s IP Literature Watch we include a paper providing an overview of the proposed alternative dispute settlement frameworks under the Data Act and...